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Alanine scanningIn view of the importance of Candida Drug Resistance Protein (Cdr1p) of pathogenic Candida albicans in azole
resistance, we have characterized its ability to efﬂux variety of substrates by subjecting its entire
transmembrane segment (TMS) 5 to site directed mutagenesis. All the mutant variants of putative 21 amino
acids of TMS 5 and native CaCdr1p were over expressed as a GFP-tagged protein in a heterologous host
Saccharomyces cerevisiae. Based on the drug susceptibility pattern, the mutant variants could be grouped
into two categories. The variants belonging to ﬁrst category were susceptible to all the tested drugs, as
compared to those belonging to second category which exhibited resistance to selective drugs. The mutant
variants of both the categories were analyzed for their ATP catalysis and drug efﬂux properties. Irrespective of
the categories, most of the mutant variants of TMS 5 showed an uncoupling between ATP hydrolysis and drug
efﬂux. The mutant variants such as M667A, F673A, I675A and P678Awere an exception since they reﬂected a
sharp reduction in both Km and Vmax values of ATPase activity when compared with WT CaCdr1p-GFP. Based
on the competition experiments, we could identify TMS 5 residues which are speciﬁc to interact with select
drugs. TMS 5 residues of CaCdr1p thus not only impart substrate speciﬁcity but also selectively act as a
communication link between ATP hydrolysis and drug transport.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionAn over expression of the drug efﬂux pump encoding CDR1 and
CDR2 genes, belonging to the ATP Binding Cassette (ABC) [1–5] and
CaMDR1, belonging to Major Facilitator (MFS) super families of
transporters [6–8], represent one of the most signiﬁcant mechanisms
of azole resistance in pathogenic Candida albicans. Among the ABC
transporters, Cdr1p is a major drug transporter of C. albicans whose
elevated expression coincides with an increased efﬂux of drug
substrates in azole resistant clinical isolates [4,9].
CaCdr1p is a 170 kDa multidrug resistance protein that belongs to
PDR subfamily of ABC transporter super family [10]. CaCdr1p has 1501
amino acids which are organized as two homologous halves. Each half
begins with a cytoplasmic hydrophilic nucleotide binding domain
(NBD) that harnesses energy through ATP hydrolysis. Each NBD isd in parts by grants to R.P. from
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ll rights reserved.followed by a highly hydrophobic transmembrane spanning domain
(TMD) comprising of six transmembrane segments (TMS), which
confer substrate speciﬁcity to CaCdr1p [2]. An enormous range of
structurally unrelated substrates compounds such as drugs, lipids and
steroids can be exported by CaCdr1p [11–13]. Experiments with
puriﬁed CaCdr1p have conclusively shown that ATP binding to Cdr1p
is not a prerequisite for drug binding and both themechanisms of drug
and ATP binding result in speciﬁc conformational changes which take
place independent of each other [14]. A direct link between the ability
of CaCdr1p to translocate ﬂuorescent glycerophospholipids and efﬂux
drugs has also been demonstrated by Shukla et al. [15].
Several structure and function studies on human ABCB1/P-
glycoprotein (P-gp) and its homologues have identiﬁed the domains
and residues involved in recognition, binding and efﬂux of drugs.
Recent cross linking studies have shown that the cytoplasmic ends of
TMS 5 and 8 of human P-gp are in close proximity on one side of the
drug binding pocket while those of TMS 2 and TMS 11 are close on the
other side of the drug binding pocket, thus forming gates for the entry
of drug substrates [16]. The multidrug transporter Pdr5p from Sac-
charomyces cerevisiae is proposed to have at least three different
substrate binding sites, each of which appears to use different
chemical properties to transport compounds [17]. In addition, several
amino acid residues that alter Pdr5p substrate speciﬁcity and
sensitivity to inhibitors have been shown to be distributed throughout
the length of protein [18–20].
1753N. Puri et al. / Biochimica et Biophysica Acta 1788 (2009) 1752–1761Considering chemically diverse substrates which are expelled by
CaCdr1p, the exact number of residues involved in drug binding and
transport are far from understood. To understand the mechanism of
drug transport mediated by CaCdr1p, we have generated its battery of
mutant variants that drastically affect various stages involved in drug
extrusion [13]. Shukla et al., 2003 have shown that the deletion of F774
in TMS 6 resulted in mislocalization of the CaCdr1p. In the same study,
by employing photo afﬁnity substrate analogs such as [125I] iodoar-
ylazidoprazosin (IAAP) and [3H] azidopine two drug binding sites on
CaCdr1p were revealed. Alanine scanning of TMS 11 of CaCdr1p
showed that at least seven residues which were critical for determin-
ing substrate speciﬁcity and drug transport were clustered on the
hydrophilic face of the α-helical projection of TMS11 [13]. Together,
these studies suggest that the drug binding sites in Cdr1p are scattered
throughout the protein and probably more than one residue of
different helices are involved in binding and extrusion of drugs.
However, there is still insufﬁcient information available to predict
where exactly the most common anti fungals, such as azoles bind and
how they are extruded.
Based on human P-gp where interactivity of different TMS is well
demonstrated [16] and our own study with CaCdr1p-GFP where we
have shown that selected residues of TMS 11 involved in drug
binding appear to be clustered in a pepwheel projection [13], in this
study, we have subjected TMS 5 of Cdr1p to site directed mutagenesis
where all the predicted 21 residues were replaced with alanine
(existing alanines were replaced by glycine). We show that most of
the residues of TMS 5 when replaced displayed decreased resistance
to tested drugs. Notwithstanding the variations in ATPase activities,
the drug efﬂux of all the mutant variants was abrogated. Our study
for the ﬁrst time shows that substitution of some of the TMS 5
residues of CaCdr1p results in uncoupling of drug transport from ATP
hydrolysis.
2. Experimental procedures
2.1. Materials
Anti-GFP monoclonal antibody was purchased from BD Bios-
ciences Clontech, Palo Alto, Calif. DNA-modifying enzymes were
purchased from NEB, USA. Protease inhibitors (Phenylmethylsulfonyl-
ﬂuoride, leupeptin, aprotinin, pepstatin A) and the drugs miconazole
(MIC), cycloheximide (CYC), ketoconazole (KTC), anisomycin (ANI),
itraconazole (ITR), R6G, β-estradiol (β-EST), progesterone (PRG),
oligomycin and other molecular grade chemicals were obtained from
Sigma Chemicals Co (St. Louis, Mo.). FLC was generously provided by
Ranbaxy Laboratories, India and tritylimidazole (tritylimz) and
tricyclohexyltinchloride (hexyltin-Cl) were kind gifts from John
Golin. The radio labeled [125I] iodoarylazidoprazosin (IAAP)
(2200 Ci/mmol) was purchased from Perkin-Elmer Life Sciences
(Boston Mass.) while [3H] Fluconazole ([3H] FLC) was custom
prepared by Amersham, UK.
2.2. Media and strains
Plasmids were maintained in Escherichia coli DH5α E. coli was
cultured in Luria-Bertani medium (Difco, BD Biosciences, NJ, USA) to
which ampicillin was added (100 μg/ml). The S. cerevisiae strain used
was AD1-8u− (MATa pdr1-3 his1 ura3 Δyor1::hisG Δsnq2::hisG Δpdr5::
hisG Δpdr10::hisG Δpdr11::hisG Δycf1::hisG Δpdr3::hisG Δpdr15::hisG),
provided by Richard D. Cannon, University of Otago, Dunedin, New
Zealand. The yeast strains used in this study are listed in the
supplementary data, Table S1. The yeast strains were cultured in
Yeast Extract Peptone Dextrose (YEPD) broth (BIO101, Vista, Calif.) or
in SD ura− dropout media (0.67% yeast nitrogen base, 0.2% dropout
mix, and 2% glucose; Difco). For agar plates, 2.5% (w/v) bacto agar
(Difco BD Biosciences, NJ) was added to the medium.2.3. Methods
2.3.1. Site speciﬁc mutagenesis of Cdr1p
Site speciﬁc mutagenesis was performed by using the Quick-
Change Mutagenesis kit from Stratagene (La Jolla, Calif.) as described
previously [21]. The mutations were introduced into the plasmid
pPSCDR1-GFP according to the manufacturer's instructions, and the
desired nucleotide sequence alterations were conﬁrmed by DNA
sequencing of the ORF. The primers used for the purpose are listed in
supplementary data, Table S2. The mutated plasmid, after linearising
with Xba1, was used to transform AD1-8u− cells for uracil prototrophy
by lithium acetate transformation protocol [21]. Integration was
conﬁrmed by Southern blot analysis.
2.3.2. Preparation of the plasma membranes and immunodetection
of Cdr1p and its mutants
The plasma membranes (PM) were prepared from S. cerevisiae
cells, as described previously [21]. The PM protein concentration was
determined by bicinchonic acid assay using bovine serum albumin as
the standard. TheWestern blot analysis was conducted using anti-GFP
monoclonal antibody (1:5000), as described previously [21]. Proteins
on immunoblots were visualized using the enhanced chemilumines-
cence assay system (ECL kit, Amersham Biosciences, Arlington
Heights, IL).
2.3.3. Confocal microscopy
The cells were grown to late log phase in SD ura−medium, except
for AD1-8u−, where uridine (0.02%) was added to the SD ura−
medium. The cells were washed and resuspended in an appropriate
volume of 50 mM HEPES (pH 7.0). The cells were imaged under an oil
immersion objective at 100× magniﬁcation on a confocal microscope
(Radiance 2100, AGR, 3Q/BLD; Bio-RAD, UK) [8].
2.3.4. Flow cytometry
Flow cytometric (FACS) analysis of CaCdr1p-GFP and its mutant
variants expressed in S. cerevisiae cells was performed with FACsort
ﬂow cytometer (Becton-Dickson immunocytometry systems, San
Jose, Calif.). Cells were grown to mid log phase and 106 cells were
harvested and washed with 50 mM HEPES (pH 7.0). Cells were
resuspended in appropriate volume of 50 mM HEPES (pH 7.0)/1×
PBS. Ten thousand cells were analyzed in acquisition. Analysis was
performed with cell quest software (Becton-Dickson immunocyto-
metry systems) [8,21].
2.3.5. Drug susceptibility
The susceptibilities of S. cerevisiae cells to different drugs were
determined using spot assays. For spot assay, 3-μl samples of ﬁvefold
serial dilutions of each yeast culture (each with cells suspended in
normal saline to an optical density at 600 nm of 0.1) were spotted
onto YEPD plates in the absence (control) or in the presence of the
drugs [22].
2.3.6. ATPase assay
The CaCdr1p-GFP associated ATPase activity of the puriﬁed PM
was measured as an oligomycin-sensitive release of inorganic
phosphate as described previously [21]. Brieﬂy, plasma membrane
suspension (10 μg of PM protein) was incubated at 30 °C in 0.1 ml
of medium containing 60 mM Tris pH 7.5 and 8 mM MgCl2
(ATPase assay buffer) and 20 μM oligomycin where indicated. To
eliminate possible contributions from non-speciﬁc vacuolar and
mitochondrial ATPases, 50 mM KNO3, and 10 mM NaN3,
respectively were included in the reaction mixture. The reaction
was started by addition of 5 mM ATP and was stopped by the
addition of 0.1 ml of 5% SDS solution. The amount of inorganic
phosphate released was determined immediately as described
previously [23].
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2.4.1. Rhodamine 6G
Efﬂux of R6G was determined essentially using a previously
described protocol [21,24]. Brieﬂy, approximately 107 yeast cells from
overnight grown culture were transferred into YEPD media and
allowed to grow for 5 h. Cells were pelleted and washed and then
resuspended in phosphate-buffered saline (PBS) without glucose as a
2% cell suspension to which R6G was added at a ﬁnal concentration of
10 μM and incubated for 1 h at 30 °C. The cells were then washed and
resuspended in PBS and reaction was initiated by the addition of 2%
glucose. Samples of 1 ml volume were withdrawn at indicated time
(30 min) and centrifuged at 9000 g for 2 min. The supernatant was
collected and absorption was measured at 527 nm. Glucose free
controls were included in all experiments. For competition assays, the
competing substrate (5×) was added to the de-energized cells 5 min
before the addition of R6G and allowed to equilibrate for an hour
before initiating the efﬂux by the addition of glucose.
2.4.2. Fluconazole
The accumulation of [3H] FLC was determined by modiﬁcation of
method described elsewhere [25]. Cells from mid log phase were
centrifuged at 3000 g for 3 min and resuspended in PBS as 5% cell
suspension (2.5×108 cells ml−1). 100 μl of cell suspension was
incubated at 30 °C and [3H] FLC was added at a ﬁnal concentration of
100 nM [speciﬁc activity 19 Ci mmol−1]. The cells were incubated
with [3H] FLC for 30 min, ﬁltered rapidly and washed twice with PBS,
pH 7.4 on millipore manifold ﬁlter assembly using 0.45 μm cellulose
nitrate ﬁlter (Millipore, USA). The ﬁlter discs were dried and put inFig. 1. Topology of yeast Cdr1p. (A) Predicted topology of CaCdr1p with two NBDs and tw
magniﬁed to show the amino acid residues. (C) The sequence alignment of protein TMS 5 re
each transporter were predicted with the program HMMTOP [38]. The scale indicates the
multiplying the frequency of that amino acid by the total information at that position. The re
the highest frequency residue at the top. The height of the symbol within each stack indi
generated using the “WebLogo” (http://weblogo.berkeley.edu/) Colors: such as green deﬁncocktail ‘O’ and the radioactivity was measured in a liquid scintillation
counter (Beckman, USA). The accumulation was expressed as pmoles
mg−1 dry weight.
2.4.3. Photoafﬁnity labeling with IAAP
The PM proteins (25 μg) were incubated with the indicated drug
for 10 min at 37 °C in 50 mM Tris–HCl (pH 7.5) in the absence of ATP.
The samples were brought to room temperature and 3 to 6 nM
iodoarylazidoprazosin [125I] IAAP (2200 Ci/mmol) was added and
incubated for additional 5 min under subdued light. The samples were
then illuminated with a UV lamp assembly (PGC, Scientiﬁcs,
Gaitherberg, MD) ﬁtted with two black light (self ﬁltering) UV-A
long wavelength F15T8BLB tubes (365 nm) for 10 min at room
temperature (21 to 23 °C). Following SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) on an 8% Tris-glycine gel at constant
voltage, gels were dried and exposed to Bio-Max MR ﬁlm (Eastman
Kodak, Rochester, NY) at −80 °C for 12 to 24 h. The radioactivity
incorporated into the CaCdr1p band was quantiﬁed using a STORM
860 phosphorimager system (Molecular Dynamics, Sunnyvale, Calif.)
and the software ImageQuaNT as described previously [21]. Western
analysis as described earlier was used to check equal loading of
CaCdr1p-GFP [21].
2.5. Statistical analysis
Data are the means±S.D from duplicate samples of at least three
independent experiments. Differences between the mean values were
analyzed by Student's t-test and results were considered signiﬁcant
when Pb0.001.o TMDs each consisting of six TMS. Each TMS is numbered. (B) The putative TMS 5 is
sidues with other fungal and mammalian transporter segments. The putative TMS 5 of
certainty of ﬁnding a particular amino acid at a given position and is determined by
sidues at each position are arranged in order of predominance from top to bottom, with
cates the relative frequency of each amino acid at that position. Sequence logos were
es polar; blue correspond to basic; red to acidic and black to hydrophobic.
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In the present study, we have systematically investigated the role
of putative TMS 5 in drug binding and transport (Fig. 1A and B).
Some of the TMS 5 residues were more conserved than the others
across fungal and mammalian ABC transporters (Fig. 1C). However,
all the 21 residues were subjected to alanine scanning. For this, we
employed site directed mutagenesis using mutagenic oligonucleo-
tides (supplementary data, Table S2). To avoid the introduction of
new side chains, the two existing alanines in TMS 5 (A660, A666)
were replaced with glycines. For functional analysis of the TMS 5
mutant variants, a heterologous hyper-expression system, where
GFP-tagged CaCdr1p is stably over expressed from a genomic PDR5
locus in a S. cerevisiae mutant AD1-8u−, was used [26]. The host
AD1-8u− developed by Goffeau's group [27], was derived from a
Pdr1–3 mutant strain with a gain of function mutation in the
transcription factor Pdr1p, resulting in constitutive hyper induction
of the PDR5 promoter [26]. A single copy integration of each
transformant at the PDR5 locus was conﬁrmed by Southern
hybridization (data not shown). Two positive clones of each GFP-
tagged CaCdr1p-mutant variants were selected to rule out any clonal
variations. We conﬁrmed that GFP tagging of CaCdr1p (CaCdr1p-
GFP) did not impair its expression and the functional activity of the
protein [21].Fig. 2. Drug resistance proﬁles of WT CaCdr1p-GFP andmutant CaCdr1p-GFP strains determin
normal saline to an A600 of 0.1. For spot assay, 3 μl of ﬁvefold serial dilutions, namely 1 (1:5)
absence (control) and presence of the following drugs: FLC (0.75 mg/l), CYC (0.02 mg/l),
hexyltin-Cl (4 mg/l), tritylimz (0.015 mg/l). Growth differences were recorded following in
solvents used for the drugs. (A) The mutant variants of ﬁrst category which exhibit suscept
included those which showed susceptibility to one or more of the drugs tested.3.1. Substitutions of TMS 5 residues with alanine decrease drug
resistance
Two positive clones of each mutant were selected and were
screened for their sensitivity to different substrates by spot assay. Our
results of drug susceptibility assay revealed that most of the cells
expressing the mutant variants of TMS 5 of CaCdr1p-GFP residues
when substituted with alanine became susceptible to tested drugs/
substrates (Fig. 2). However, their extent of sensitivity to various
drugs was variable (discussed below). Based on the drug suscept-
ibility results, all the mutant variants could be placed into two
categories: The ﬁrst category included seven residues T658A, A660G,
T661A, V662A, L665A, I669A and Y670A. These showed hyper
susceptibility comparable to host AD1-8u− cells for all the tested
drugs (Fig. 2A). The second category, comprising of fourteen mutant
variants, P659A, L663A, L664A, A666G, M667A, V668A, T671A,
G672A, F673A, V674A, I675A, P676A, T677A and P678A displayed a
selective loss of resistance to one or more of the tested drugs (Fig.
2B). Residue A666, when replaced with glycine (A666G), displayed
hyper resistant phenotype towards FLC comparable to wild type
(WT) CaCdr1p-GFP expressing cells but showed considerable
sensitivity to other drug substrates (Fig. 2B). P659A, T671A, V674A,
and P678A mutant variants which showed signiﬁcant resistance to
both hexyltin-Cl and R6G were highly sensitive to most of the testeded by Spot assay. Cells were freshly streaked, grown overnight and then resuspended in
, 2 (1:25), 3 (1:125) and 4 (1:625), of each strain was spotted on to YEPD plates in the
ITR (0.08 mg/l), KTC (0.05 mg/l), MIC (0.03 mg/ml), ANI (0.4 mg/l), R6G (0.6 mg/l),
cubation of the plates for 48 h at 30 °C. Growth was not affected by the presence of the
ible phenotype for all the tested substrates. (B) The mutant variant of second category
Fig. 3. Expression and drug binding assay using plasmamembranes cells expressingWT CaCdr1p-GFP and the mutant variants of TMS 5 in S. cerevisiae. (A)Western analysis showing
propermembrane localization ofWT CaCdr1p-GFP and its mutant variants. (B) Photo afﬁnity labeling ofWT CaCdr1p-GFP and its mutant variants with [125I] IAAP in the presence and
absence of NYS. The PM proteins (25 μg) were photoafﬁnity labeled with [125I] IAAP under subdued light as described in Experimental procedures. Upper panel, lane 1, WT CaCdr1p-
GFP (no drug); lane 2,WT CaCdr1p-GFP with NYS; lanes 3, 5, 7 show [125I] IAAP binding inmutant variants of CaCdr1p-GFPwithout drugwhile lanes 4, 6, 8 exhibit [125I] IAAP binding
in the presence of 200 μM NYS. Lower panel depicts Western analysis to show equal loading of CaCdr1p-GFP.
Table 1
Comparison of ATPase activity of CaCdr1p with its mutant variantsa.
Strain Km (mM) Vmax (nmol min−1 mg protein−1)
CaCdr1p-GFP 6.39±0.46 129.87±3.68
T658A 7.55±0.20 120.49±1.02
P659A 4.82±0.08 107.45±2.58
A660G 7.19±0.14 116.84±5.76
V662A 5.71±0.71 114.13±6.27
L663A 3.62±0.38 105.19±4.99
L664A 4.06±0.13 112.41±1.78
L665A 3.73±0.40 100.70±3.22
A666G 6.08±0.62 119.69±11.74
M667A 2.68±0.01 81.64±0.707
V668A 5.69±0.41 106.81±4.81
I669A 4.04±0.11 93.07±2.17
Y670A 3.62±0.29 88.18±1.91
T671A 4.36±0.12 91.74±0.59
G672A 5.21±0.32 101.74±2.89
F673A 3.92±0.10 78.195±1.72
V674A 4.75±0.36 92.87±3.64
I675A 1.58±0.13 76.09±1.43
P676A 4.83±0.45 114.23±6.34
T677A 4.90±0.47 103.02±4.85
P678A 2.70±0.87 83.75±9.42
a ATPase activity of the PM fraction of cells expressing the wild type Cdr1p and its
mutant variants were assayed as described under Experimental procedures; the values
represent the average±standard deviation of three independent experiments.
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L663A, L664A, G672A, F673A, I675A, P676A and T677A mutant, the
above mentioned variants also showed partial resistance to FLC. The
mutant variants L663A, L664A, M667A, V668A, G672A, F673A and
T677A were partly resistant to R6G but were susceptible to other
tested substrates and the two variants I675A and P676A exhibited
partial resistance to hexyltin-Cl and FLC in comparison to other tested
substrates (Fig. 2B). While most of the mutant variants of second
category exhibited modest resistance to FLC but it was not the case
with the two mutant variants M667A and V668A. Of note, when
replaced with alanines/glycines, the abrogation in drug resistance
was seen with all the variants, irrespective of the fact whether the
residue of TMS 5 of CaCdr1p belonged to conserved or non-conserved
category (Figs. 1C and 2). Notably, the expression of CaCdr1p as
revealed by immunoblot analysis employing anti-GFP monoclonal
antibody and confocal analysis was similar to WT CaCdr1p-GFP
protein in all the mutant variants except in T661A which was
mislocalized and thus it was not detected in the plasma membrane
(PM) (Fig. 3A). As the expression of T661A in the PM was negligible,
this mutant was not taken for further characterization.
3.2. ATPase activity of most of the mutant variants remains unaffected
To test the possibility that the introducedmutations in TMS 5 have,
in any way, altered the catalytic cycle of CaCdr1p, which might have
resulted in impaired efﬂux of substrates, we checked the basal ATPase
activity. We have used heterologous host S. cerevisiae deleted in eight
ABC transporters [27] to over express CaCdr1p and thus have
minimum background ATPase activity interference from other similar
proteins. To eliminate possible contributions from non-speciﬁc
vacuolar and mitochondrial ATPases, 50 mM KNO3, and 10 mM
NaN3, respectively were included in the reactionmixture [21]. Of note,
our earlier studies established that there was no signiﬁcant drug
stimulated ATPase activity elicited by CaCdr1p in presence of drug
substrates [14]. For routine ATPase assay, the puriﬁed PM from WT
CaCdr1p-GFP as well as from mutant CaCdr1p-GFP variants were
analyzed for their oligomycin-sensitive ATPase basal activity (without
drug substrates) [21]. ATPase activities of most of the mutants at a
ﬁxed nucleotide concentration (ATP 5 mM) did not show any
difference between mutants and the wild type protein expressing
cells (data not shown). However, a more rigorous kinetic analysis
employing Lineweaver Burke plots, revealed kinetic differences in
ATPase activity of various mutant variants. For example, in mutants
such as T658A, A660G, V662A, A666G and V668A, there was no
signiﬁcant change in Km and Vmax values. However, in the other set of
mutants such as P659A, L663A, L664A, L665A, I669A, Y670A, T671A,G672A, V674A, P676A and T677A, there was a modest decrease in
apparent Km (not exceeding 20%), but all these mutants were able to
attain Vmax in the same range as of WT CaCdr1p-GFP. Therefore, these
mutants seem to uncouple ATP catalysis from drug efﬂux (Table 1).
However, this was not the case with M667A, F673A, I675A and P678A
mutants where both the Km and Vmax values showed a signiﬁcant
decrease (Table 1).
3.3. Drug binding remains unaffected in mutant variants
In order to explore whether the observed differences in drug
susceptibilities accompanied by abrogated efﬂux activities were due
to any aberration in drug binding, some of the mutants based on their
selective sensitivity to drugs (Fig. 2) were analyzed for their drug
binding abilities. For this we used iodoarylazidoprazosin [125I] (IAAP)
which is a photo afﬁnity analog of CaCdr1p substrate prazosin. We had
earlier shown that [125I] IAAP which has been extensively used to map
human P-gp drug binding sites also binds toWT CaCdr1p-GFP and can
be competed out with nystatin (NYS) [21]. It was observed that the
drug binding properties of the TMS 5 mutant variants of CaCdr1p-GFP
remained unaffected and were similar to WT CaCdr1p-GFP (Fig. 3B).
1757N. Puri et al. / Biochimica et Biophysica Acta 1788 (2009) 1752–17613.4. Enhanced drug sensitivity of the TMS 5 mutants is associated
with reduced efﬂux of substrates
Since there was no detectable difference in ATP hydrolysis, we
checked if the observed drug sensitivity by CaCdr1p mutant variant
expressing cells was associated with impaired drug extrusion. For this,
twowell known substrates of CaCdr1p such as R6G and FLC were used
to monitor the drug efﬂux activity [28]. Both ﬂuorescent R6G and [3H]
FLC were allowed to equilibrate in the de-energized cells by passive
diffusion and the energy dependent extrusion was then initiated by
the addition of glucose. As depicted in Fig. 4A (inset), after glucose
addition, WT CaCdr1p-GFP expressing cells demonstrated energy
dependent efﬂux of R6G (increase in extra cellular concentration)
which is not seen in AD1-8u− cells. Notably, a 40–60% decrease in the
extra cellular concentration (due to low efﬂux) of R6G was observedFig. 4.Drug transport assays inWT CaCdr1p-GFP andmutant variants of TMS 5. (A) R6G efﬂux
the extra cellular concentration of R6G in presence and absence of glucose in AD1-8u− and
section. (B) FLC accumulation in WT CaCdr1p-GFP and mutant CaCdr1p-GFP variant expre
absence of glucose in AD1-8u− and WT CaCdr1p-GFP. The results are means±standard devin the TMS 5 mutant variants as compared to that in theWT CaCdr1p-
GFP cells, which clearly indicated impaired efﬂux activity by the
mutant cells (Fig. 4A). The accumulation due to passive diffusion of
R6G and [3H] FLC in the de-energized cells in the mutant variants was
comparable to that in theWT CaCdr1p-GFP (data not shown). That the
efﬂux ability of the TMS 5 mutant cells was reduced was further
conﬁrmed by using another substrate, [3H] FLC. The inset in Fig. 4B
shows energy dependent decrease in accumulation of FLC in cells
expressing WT CaCdr1p-GFP which was not the case with AD1-8u−
cells. Fig. 4B depicts that the intracellular levels of accumulation of
[3H] FLC were 43–65% higher (due to lower levels of efﬂux) in the
mutant cells than the WT CaCdr1p-GFP. Notably, most mutations
displayed impaired efﬂux, irrespective of the categories based on drug
resistance proﬁle (Fig. 4A and B). All the changes observed in R6G
efﬂux are statistically signiﬁcant (Pb0.001).inWT CaCdr1p-GFP andmutant CaCdr1p-GFP variant expressing cells. The inset shows
WT CaCdr1p-GFP. The assay was performed as described in Experimental procedures
ssing cells. The inset shows the intracellular accumulation of [3H] FLC in presence and
iations for three independent experiments.
Fig. 5. Competition of various drugs with R6G in WT CaCdr1p-GFP. For competition between R6G and various drugs, R6G was used at a ﬁnal concentration of 10 μM and a ﬁvefold
concentration of each drug (50 μM), KTC, MIC, ITR, FLC, CYC, ANI, EST and PRGwas used for competition studies. KTC, MIC, ITR compete for R6G inWT CaCdr1p-GFP. (A) Efﬂux of R6G
in AD1-8u− cells in presence of different substrates. (B) Efﬂux of R6G in presence of different substrates in cells expressing WT CaCdr1p-GFP. The results are means±standard
deviations for three independent experiments.
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L665A displays an increased R6G efﬂux but shows no resistance to
R6G in Fig. 2. The opposite is true for L664A, T671A, and V674A. The
mutants A660G, L665A or I669A show a decreased FLC intracellular
accumulation level, but in the spot assay they do not show any
resistance to FLC. Also, the resistance showed by mutant variant
A666G towards FLC on spot assay was not reﬂected in FLC transport
assay. It should be pointed out that the two parameters, drug efﬂux
and drug sensitivity do not directly match, hence, should be
considered independently. For example, susceptibility to FLC/R6G
could be due to culmination of factors other than an over expression of
efﬂux pump proteins while the efﬂux of the drugs is directly
dependent on MDR pump proteins such as CaCdr1p in this case.
In the following experiment, R6G efﬂux was competed out with
ﬁve fold molar excess CaCdr1p substrates such as KTC, ITR, MIC, FLC,
ANI, PRG, β-EST and CYC (Fig. 5). In comparison to AD1-8u− cells
where no change in the extra cellular concentration of R6G was
observed (Fig. 5A), substrates such as ITR, KTC andMIC could compete
with R6G efﬂux (up to three fold) in the cells expressingWT CaCdr1p-
GFP. The other substrates like FLC, ANI, CYC, PRG and EST could not
signiﬁcantly compete with R6G (Fig. 5B).
We evaluated if R6G efﬂux in mutant variants of TMS 5 owing to
loss of residues still retained the ability to be competed with KTC, ITR
and MIC. Since, the inhibition of R6G efﬂux varies between 40% and
65% (Fig. 4A); the residual activity in these mutant variants was taken
as their 100% activity for fold change calculations. As shown in Fig. 6A,
B and C, the ability of KTC, MIC and ITR to compete with R6G efﬂux
was severely abrogated in most of the TMS 5 mutants resulted in an
increase in extracellular concentration of R6G between 1.8 and 6.8
folds. The mutant variant T658A was an exception as its R6G efﬂux
was comparable to that of WT CaCdr1p in presence of MIC. All thechanges observed in R6G efﬂux in the presence of different drugs like
KTC, ITR and MIC are statistically signiﬁcant (Pb0.001).
4. Discussion
Cdr1p of C. albicans belongs to ABC super family of primary
transporters which directly couples ATP hydrolysis to substrate/drug
transport. These ABC pump proteins such as Cdr1p and Cdr2p of C.
albicans not only efﬂux azoles and its derivatives but also extrude a
variety of structurally unrelated compounds. It is the promiscuity in
substrates speciﬁcity which is intriguing and challenging in
designing modulators/inhibitors of CaCdr1p. To this end, it is
essential to understand, how drugs bind and how their efﬂux is
powered by ATP hydrolysis. Based on studies from human ABC
multidrug transporter P-gp where TMS 11 is predicted to interact
with TMS 5 and our own data where some residues of TMS 11 have
been shown to be critical; in the present study, we have subjected
entire TMS 5 of CaCdr1p to alanine scanning to gain an insight into
its involvement in drug binding and transport. For this, all the
putative 21 residues were subjected to site directed mutagenesis
and replaced with alanine.
Our results of drug susceptibility by spot assays revealed that all
the mutants displayed increased susceptibility to the tested drugs.
Essentially, all the mutants could be clustered in two groups: 1)
included T658A, A660G, T661A, V662A, L665A, I669A and Y670A
which displayed susceptibility to all tested drugs, 2) included P659A,
T671A, V674A, P678A L663A, L664A, M667A, V668A, G672A, F673A,
T677A, I675A and P676A which showed varying degree of suscept-
ibility to different drugs. For example, the mutant variants of group 2
such as L663A, L664A, M667A, V668A, G672A, F673A and T677Awere
only moderately resistant to FLC and R6G while mutant variants
Fig. 6. Competition of various drugs inmutant variants of CaCdr1p-GFPwith R6G. For competition between R6G and various drugs, R6Gwas used at a ﬁnal concentration of 10 μMand
a ﬁvefold concentration (50 μM) of each competing drug KTC, MIC and ITRwas added. Panels A, B and C show the percentage values of R6G efﬂux of mutant variant expressing cells in
presence of KTC, ITR and MIC, respectively. Unlike in WT CaCdr1p-GFP, R6G efﬂux by all the mutant variants was no longer competed out by ITR, KTC and MIC. The results are means
±standard deviations for three independent experiments.
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FLC which was comparable to WT CaCdr1p-GFP.
Golin et al. [17] have used imidazole and trialkyltin chloride
derivatives to determine theminimumprerequisite of Pdr5p substrate
interaction and transport. In this study, we tested the susceptibility of
CaCdr1p mutant variants towards one such imidazole namely
tritylimz and trialkyltin chloride derivative, i.e. hexyltin-Cl. Interest-
ingly, most of the mutant variants of TMS 5 became hypersusceptible
towards both the compounds. However, mutant variants namely,
P659A, T671A, V674A, I675A, P676A and P678A exhibited varying
degrees of resistance to hexyltin-Cl and in parallel showed moderate
resistance to FLC and R6G. These results are interesting in the light of
our earlier results where selected critical residues of TMS 11 showed
opposite effect to these compounds. All the mutant variants of TMS 11
remained resistant to hexyltin-Cl while seven of themwere selectively
sensitive to tritylimz [13]. It is clear that unlike TMS 11, the residues of
TMS 5 are involved in coordinating interactions with both hexyltin-Cl
and tritylimz. Though the simple aromatic imidazole derivative,
tritylimz used in this study differs dramatically in structure from the
alkyltin compound, hexyltin-Cl, but they overlap in their size andhydrophobicity values and have also been shown to bind at the same
site in Pdr5p [17]. This explains why both these compounds are able to
evoke similar responses from the mutant variants because of their
probable similar interactions with residues of TMS 5 which was not
the case with TMS 11 residues. Taken together, the display of selective
sensitivity by these mutant variants of TMS 5 suggests that some of
the residues appear to be critical for establishing interactions with
selected drugs. Notably, the observed phenotypic differences dis-
played by the mutant variants of TMS 5 were regardless of location of
residue within the helix; the degree of conservation of the residue or
the nature of the side chain of the amino acid residues (Fig. 1). This is
interesting in the context of TMS 11 where only selected residues are
involved in drug binding which seem to cluster on one face of the
helix [13].
We have earlier observed that in the WT CaCdr1p-GFP except for
selected azoles such as KTC, MIC and ITR, none of the other tested
substrates could compete with R6G efﬂux. This suggested that KTC,
MIC and ITR may share binding sites with R6G on CaCdr1p-GFP. In the
present study, it is evident from competition assays that efﬁcient
competitors of R6G efﬂux, such as KTC, MIC and ITR, became totally
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exception to this was the residue T658 which upon mutation to
alanine continued to efﬂux R6G in a similar manner as the WT
CaCdr1p in the presence of MIC and thus ruling out its involvement
towards MIC binding. Therefore, the residues of this TMS appear to be
crucial to substrate recognition and extrusion. Taken together; it
appears that similar to human P-gp, CaCdr1p has multiple binding
sites [29]. One of the site(s) is probably responsible for translocation
of R6G and the azoles like KTC, MIC and ITR while another site(s) can
only interact and transport substrate such as FLC. There could still be
third binding site where prazosin analog IAAP binds.
There are essentially four steps involved in drug extrusion: ATP and
drug binding, ATP hydrolysis and drug release. Since our mutant
variants displayed decreased resistance to selective drugs, we
analyzed each step to pinpoint the defect leading to increased drug
susceptibilities. For this, basal ATPase activities of all the mutant
variants were measured. In most mutants, there was no signiﬁcant
change in Km and Vmax values. Notwithstanding the status of ATPase
activity, the drug efﬂux in all the mutants was considerably reduced.
Our drug binding results with representative CaCdr1p substrate [125I]
(IAAP) also showed that the drug binding ability of TMS 5 mutant
variants remained unaffected in comparison to WT CaCdr1p-GFP. In
this context, it is essential to mention that since we have used a
representative substrate, prazosin's photoafﬁnity analog [125I] (IAAP)
for drug binding, the possibility of its binding to another site(s) on
CaCdr1p cannot be excluded. It should also be pointed out that while
IAAP binding to CaCdr1p is ATP independent, binding of ﬂuorescent
R6G to plasma membrane of ScPdr5p overproducing cells was ATP
dependent which could be competitively inhibited by estradiol
derivative RU49953 [30–31]. A detailed binding study employing
IAAP and other substrate analogues would help to resolve the nature
of drug binding pocket harboured by CaCdr1p.
The structure of bacterial ABC transporter Sav 1866, which may be
considered as a functional ortholog of ScPdr5p, human P-gp, ABCG2p
and CaCdr1p, has been resolved to 3Ǻ [32]. The 3D structure of Sav
1866 for the ﬁrst time conﬁrms signiﬁcant contacts between the TMDs
and NBDs. These contacts occur via intracellular loops that link TMS
helices. This structure organization offers a possible explanation for
the mechanical coupling between the NBDs and the TMDs of ABC
transporters which is consistent with the genetic data that implicated
ICL1 of human MDR1 to interact with NBDs [33]. The mutational
studies and sequence comparisons also indicated that ICL2 of TAP1/
TAP2, as well as, ICL4 of CFTR provide similar crucial contacts [34]. In
addition, studies on P-gp and Yor1p using site directed mutagenesis
and cross linking agents have demonstrated the close proximity of
ICL2 and Q loop of NBD1 [35]. A study by Sauna et al. [36], have shown
a cross talk between NBD1 and Transmembrane helix 2 in a CaCdr1p
homologue, Pdr5p of S. cerevisiae. Taken together, it is now fairly
established that the TMDs of these transporters, all featured strikingly
similar, short α-helices located in their cytoplasmic loops between
TMS which provide the bulk of contacts to NBDs and have been
labeled as coupling helices [37]. ABC transporters functionality hinges
on precise coupling of ATP hydrolysis which occurs at NBDs and with
drug transport which occurs at TMDs. In CaCdr1p, ICL2 links TMS 4
and 5 and ICL4 links TMS10 and 11, however, how they mechanically
couple ATP hydrolysis with drug transport is not established.
However, taking clues from Sav 1866 3D structure and recent study
of ScPdr5p by Golin's group, it is reasonable to speculate that ICL2 and
4 of CaCdr1p function as communicating links between TMS 4:5 and
TMS 10:11, respectively. We had earlier shown that similar to TMS 5,
some of the TMS 11 mutant variants also display uncoupling between
ATP catalysis and drug transport. Therefore, probably some mutations
in TMS 5 (present study) and 11 result in conformational changes
which limit the interaction between NBDs and TMDs via ICL 2 and 4.
This in turn results in futile ATP hydrolysis which is uncoupled from
the drug transport. Alternatively, residues in TMS 5 have also beenseen to affect the kinetics of the coupling between ATPase activities;
substrate binding and efﬂux activity. The exact mechanism of drug
transport remains speculative at this point till we have 3D structural
details of CaCdr1p. These aspects are actively being pursued as second
phase of work.
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